Although low-grade parasite persistence is a fundamental aspect of chronic Chagas disease, current parasitological assays have low sensitivity and are not quantitative. Benznidazole, the only available trypanocidal drug, has questionable efficacy in the treatment of chronic Chagas disease patients. There is an urgent need to perform clinical trials of new drugs for chronic Chagas disease, however the lack of reliable biomarkers for reduction of parasitism and consequent inflammatory responses and damage is a major obstacle for evaluating new drugs. The identification of differentiating markers for presence and levels of 7. crtvz;parasitism and resulting immune and inflammatory perturbations could potentially solve this problem. The few available biomarkers for parasitism and disease progression are neither quantitative nor highly predictive. It is known that composite biomarkers have a higher potential for differentiating clinical outcomes than single markers. Blood gene expression profiling has been used to differentiate between patients with distinct courses of infection in several infectious diseases including preliminary data from our group for Chagas disease. We hypothesize that persistent parasitism by 7. cruzi, induces specific changes in PBMC gene expression patterns. A second hypothesis is that distinct stages of infection, defined based on clinical presentation and findings and 7. cruzi PCR and antibody results, will display specific composite biomarker profiles. The major aims of this project are to identify the transcriptional profiles of high and low 7. cruzi parasitism as well as the transcriptional profiles of patients with different clinical presentations, and to combine the findings from transcriptome analyses with other biomarker parameters we are currently characterizing. The study will evaluate a sample of patients representative of distinct clinical stages of Chagas disease and intensity of parasitism (as measured by 7. cruzi real-time PCR), along with seronegative controls, from the REDS II Chagas cohort. Transcriptome analysis of whole blood will be performed, and transcriptional signatures that correlate with each clinical group will be validated with qPCR assays that can be applied to larger sample sets. We will then test the classifying ability of validated mRNA markers on the remainder of the REDS II Chagas disease cohort (600 patients and 100 seronegative controls). Plasma protein biomarkers of inflammation and cardiovascular disease and 7. cruz/antibody profiles/titers, which are being characterized in the same patient groups, will be combined with transcriptome signatures to construct an improved composite biomarker profile for prognosis and therapeutic monitoring.
Chronic Chagas disease affects 10 million people, and the only available drug against Trypanosoma cruzi is marginally effective and has serious side effects. Current tests for Chagas patients have poor prognostic predictive value and do not show if treatment eliminates the parasite or reduces inflammation and end-organ damage. The proposed identification of improved tests for 7. cmzi infection will allow for improved patient management and evaluation of new,anti-7. cruzi drugs to be used in millions of patients.
|Ferreira, Ludmila Rodrigues Pinto; Ferreira, Frederico Moraes; Nakaya, Helder Imoto et al. (2017) Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction. J Infect Dis 215:387-395|
|Capuani, Ligia; Bierrenbach, Ana Luiza; Pereira Alencar, Airlane et al. (2017) Mortality among blood donors seropositive and seronegative for Chagas disease (1996-2000) in São Paulo, Brazil: A death certificate linkage study. PLoS Negl Trop Dis 11:e0005542|
|Ferreira, Ariela Mota; Sabino, Ester Cerdeira; de Oliveira, Lea Campos et al. (2016) Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil. PLoS One 11:e0165950|
|Cardoso, Clareci Silva; Sabino, Ester Cerdeira; Oliveira, Claudia Di Lorenzo et al. (2016) Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile. BMJ Open 6:e011181|
|Keating, S M; Deng, X; Fernandes, F et al. (2015) Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease. Int J Cardiol 199:451-9|
|Tanowitz, Herbert B; Machado, Fabiana S; Spray, David C et al. (2015) Developments in the management of Chagas cardiomyopathy. Expert Rev Cardiovasc Ther 13:1393-409|
|Carmo, Andre A L; Rocha, Manoel O C; Silva, Jose L P et al. (2015) Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease. Int J Cardiol 189:182-4|
|Navarro, Isabela Cunha; Ferreira, Frederico Moraes; Nakaya, Helder I et al. (2015) MicroRNA Transcriptome Profiling in Heart of Trypanosoma cruzi-Infected Mice: Parasitological and Cardiological Outcomes. PLoS Negl Trop Dis 9:e0003828|
|Capuani, Ligia; Bierrenbach, Ana Luiza; Abreu, Fatima et al. (2014) Accuracy of a probabilistic record-linkage methodology used to track blood donors in the Mortality Information System database. Cad Saude Publica 30:1623-32|
|Abel, Lúcia Cristina Jamli; Ferreira, Ludmila Rodrigues Pinto; Cunha Navarro, Isabela et al. (2014) Induction of IL-12 production in human peripheral monocytes by Trypanosoma cruzi Is mediated by glycosylphosphatidylinositol-anchored mucin-like glycoproteins and potentiated by IFN- ? and CD40-CD40L interactions. Mediators Inflamm 2014:345659|